Absence of interaction between furosemide and mitomycin C

Area of Science:

• Pharmacology
• Clinical Pharmacy
• Drug Interactions

Background:

• Mitomycin C (MMC) is an anticancer agent.
• Furosemide is a diuretic commonly prescribed for various conditions.
• Potential drug interactions require careful evaluation to ensure patient safety.

Purpose of the Study:

• To investigate the potential pharmacokinetic interaction between furosemide and mitomycin C (MMC).
• To determine if furosemide administration affects the absorption, distribution, metabolism, or excretion of MMC.

Main Methods:

• Pharmacokinetic study involving five patients.
• High-Performance Liquid Chromatography (HPLC) assay used for MMC quantification.
• Furosemide administered before or after MMC to assess impact.

Main Results:

• Furosemide administration did not alter the pharmacokinetic profile of mitomycin C.
• Urinary excretion of mitomycin C remained unchanged despite furosemide co-administration.
• No significant adverse events related to the drug combination were noted.

Conclusions:

• Furosemide does not appear to interact with mitomycin C based on pharmacokinetic parameters.
• This finding suggests that concurrent use of these drugs may be safe from a pharmacokinetic perspective.
• Further clinical studies may be warranted to confirm these findings in broader patient populations.